| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6ae3a956054a5b4dd96686a962474809
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d84aa8c4818bda002eded1de6d318389 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F15-0033
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F15-0046
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F13-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F15-008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F15-0093
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F15-004
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F15-0073
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F13-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2018-08-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2022-01-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4c43322089acd47d90fb73a88b98f8a1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_79fb0aacf409c17ed4176c686e5d454f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4e18f46359970d66f016064dc81eb807
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0bd18e47945309af45a438100be3eebe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fda2e6840ef52db3ea66193e85c2b5e4 |
| publicationDate |
2022-01-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-11214586-B2 |
| titleOfInvention |
Rhodamine triplet state complex and preparation and photodynamic therapy (PDT) study thereof |
| abstract |
Through the use of a rhodamine appended chelate, a versatile strategy has been demonstrated to generate mitochondria-targeting photosensitizers via the incorporation of variety of luminescent transition metal systems. The generation of triplet excited state of rhodamine moiety endows the complexes with mitochondria-targeting photosensitizing ability to form singlet oxygen ( 1 O 2 ) for use as photodynamic therapy (PDT) agent. The combination of rhodamine organic dye and luminescent transition metal centers in such hybrid systems exhibits the synergistic merits, including low dark cytotoxicity, selective tumor cell uptake, high molar absorptivity for low-energy excitation in the visible region, and high photostability. |
| priorityDate |
2018-08-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |